In the SENS6 Conference’s keynote address, Harvard University’s Dr. George Church describes recent advances in genomics and in the reading, writing, and interpretation of -omes fields. He also discusses PersonalGenomes.org, his initiative to glean new medical insights by gathering data on the genotypes, microbiomes, environments, traits, and stem cells of participants. He proceeds to cover various methods of improving RNA sequencing to gather data on transcriptomes, then provides additional detail on engineering therapeutics for individual patients. Before concluding, Dr. Church discusses protective alleles and offers a broad overview of genomic engineering strategies. In particular, he notes the considerable promise the CRISPR approach holds for the field.
Three ways to resolve crowded RNA sequences
1. Super-resolution 400 — 10 nanometers
2. Molecular stratification
Get something rare or synthetic into rest of population – rejuvenated field of Gene Therapy
RNA guided human genome engineering – CRISPR-HR 9 to 22 times better. 7% accuracy
83,000 base pair deletions
Increasingly precise gene replacement
Multiplex Chip synthesis
Find out what to fix, Fix the Genome, Fix Epigenome and use non-human genes if needed to achieve superhealth
Mike Kope, President and CEO of SENS Research Foundation, delivers his SENS6 presentation in this video. He begins by showcasing SRF’s updated website and messaging materials, including its new annual and research reports. Mike follows this with an overview of the fundamental research approach that SRF advocates: periodically repairing the damage that causes age-related disease instead of trying to intervene in metabolism and late-stage pathology. He then describes the challenges that face SRF in trying to build a rejuvenation biotech industry – in particular, the need to establish credibility and build support for the damage-repair paradigm. Mike explains how SRF is answering that challenge by highlighting SRF’s research project to treat heart disease by degrading 7-ketocholesterol (a toxic molecule found in atherosclerotic plaques) as well as the new world-class scientific animations found on www.sens.org. In closing, he optimistically notes the effect that results-based healthcare systems (which are beginning to emerge in parts of the world without entrenched process-based systems) might have on regulatory bodies in the US and Europe.
In this interview, Dr. Aubrey de Grey, SENS Research Foundation’s Chief Science Officer, talks about SENS6 and the ever-increasing impact of the SENS Conference series. First, Dr. de Grey discusses the accelerating scientific progress that makes each conference better than the last and highlights the growing contribution of SRF-funded research to the field of regenerative medicine. He then describes the dueling viewpoints that still debate the role of aging in age-related disease. Finally, Dr. de Grey closes by enumerating SRF’s major achievements over the past couple of years and describes his hopes and expectations for the Foundation’s future.
In this interview, SENS Research Foundation President and CEO Mike Kope describes the buzz and praise the SENS6: Reimagine Aging Conference generated from attendees. In particular, he mentions the excellent networking opportunities afforded to attendees by the Conference as well as inroads the Foundation was able to build in the scientific community. Dr. Church’s endorsement of SRF is a bold example, and Mike looks forward to even more support for the Foundation’s goals and message in the future.